Clinical Trials on Histoplasmosis in New Zealand

Total 5 results

National Institute of Allergy and Infectious Diseases...

Completed

Withdrawal of Antifungal Treatment for Histoplasmosis in Patients After Improved Immune Response to Anti-HIV Drugs

HIV Infections | Histoplasmosis

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Study of Itraconazole in Preventing the Return of Histoplasmosis, a Fungal Infection, in Patients With AIDS

HIV Infections | Histoplasmosis

United States
National Institute of Allergy and Infectious Diseases...
Janssen Pharmaceuticals

Completed

A Study of Itraconazole in the Treatment and Prevention of Histoplasmosis, a Fungal Infection, in Patients With AIDS

HIV Infections | Histoplasmosis

United States
National Institute of Allergy and Infectious Diseases...
Pfizer

Completed

Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome

HIV Infections | Histoplasmosis

United States
Scynexis, Inc.

Completed

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)

Coccidioidomycosis | Invasive Pulmonary Aspergillosis | Allergic Bronchopulmonary Aspergillosis | Histoplasmosis | Chronic Pulmonary Aspergillosis | Blastomycosis | Invasive Candidiasis | Recurrent Vulvovaginal Candidiasis | Mucocutaneous Candidiasis | Other Emerging Fungi

United States, Spain, United Kingdom, Austria, Pakistan, South Africa, Germany, Netherlands

Clinical Trials on Histoplasmosis in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations